Table 1 Clinicopathologic factors and aspartyl beta-hydroxylase expression in hepatocellular carcinomas based on immunohistochemistry

From: Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma

Variables

n

ASPH immunoreactivity

P

  

—

Low

High

 

Sex

 M

116

7

25

84

NS

 F

45

4

8

33

 

Age

 Less than median

78

5

20

53

NS

 Greater than median

83

6

13

64

 

Serum AFP level (μg/l)

 <20

55

4

12

39

NS

 ≥20

106

7

21

78

 

HBsAg

 Positive

122

8

22

91

NS

 Negative

39

3

10

26

 

Tumor size

 ≤2 cm

48

4

8

36

NS

 >2 cm

113

7

25

81

 

Histological grade

 Well differentiated

53

5

18

30

 

 Moderately differentiated

80

4

13

62

0.018

 Poorly differentiated

28

2

2

24

0.006

Liver cirrhosis

 Absent

66

4

14

48

NS

 Present

95

7

19

69

 

Tumor capsule

 Intact

48

4

13

31

NS

 Absent or not intact

113

7

20

86

 

Intrahepatic metastasis

 Not observed

54

5

16

33

0.036

 Observed

107

6

17

84

 

Total

161

11

33

117

 
  1. P=0.018 (well differentiated vs moderately differentiated); P=0.006 (well differentiated vs poorly differentiated); P=0.036 (not observed intrahepatic metastasis vs observed intrahepatic metastasis).
  2. ASPH: aspartyl beta-hydroxylase.
Back to article page